Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Ataxia telangiectasia and Rad3 related (ATR; FRP1)

Rodent and cell culture studies identified sulfonyl-morpholino-pyrimidine-based ATR inhibitors that could help treat cancer. In a human colorectal cancer cell line, the lead compound caused 50% growth inhibition at nanomolar concentrations. In a mouse xenograft model for human colorectal cancer, oral treatment with the compound decreased tumor growth compared with vehicle treatment. Next steps could include testing the lead ATR inhibitor in models for other cancer types.

SciBX 6(8); doi:10.1038/scibx.2013.187
Published online Feb. 28, 2013

Patent application filed; licensing status unavailable

Foote, K.M. et al. J. Med. Chem.; published online Feb. 11, 2013;
doi:10.1021/jm301859s
Contact: Kevin Michael Foote, AstraZeneca plc, Cheshire, U.K.
e-mail:
kevin.foote@astrazeneca.com